Clinical experience with the addition of pramlintide in patients with insulin-requiring type 2 diabetes.
Elkind-Hirsch
Karen
K
Metabolic Center of Louisiana Research Foundation, 7566 Picardy Ave., Baton Rouge, LA 70808, USA. karen.elkind-hirsch@womans.org
Butler
William J
WJ
Bhushan
Madhu
M
Hirsch
David
D
Bhushan
Rajat
R
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000682:Amyloid / Q000627:therapeutic use*; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D001823:Body Composition; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use*; D058228:Islet Amyloid Polypeptide; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies
D000682:Amyloid; D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D058228:Islet Amyloid Polypeptide; C105254:pramlintide